Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with nonvalvular atrial fibrillation.
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastsatin, and simvastsatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus.
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Compared with prescription of pioglitazone, prescription of rosig litazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increase risk of the composite of AMI, stroke,heart failure, or all- cause mortality in patients 65 years or older.
Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.
Children and youth prescribed antipsychotics had an increased risk of type 2 diabetes that increased with cumulative dose, and the risk increased significantly with increasing cumulative dose.
The role of databases in drug postmarketing surveillance
- Evelyn M. Rodriguez, J. Staffa, D. Graham
- Political SciencePharmacoepidemiology and Drug Safety
- 1 August 2001
The role of databases used for postmarketing surveillance of drugs at the United States Food and Drug Administration (FDA) are described and the Adverse Event Reporting System (AERS), the largest database of adverse event reports in the world, is described.
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Treatment with rivaroxaban 20 mg once daily was associated with statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily, which indicated increased risk of stroke, bleeding, and mortality in patients with nonvalvular atrial fibrillation.
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study
Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.